BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 12662139)

  • 1. New directions in natural killer cell-based immunotherapy of human cancer.
    Farag SS; Fehniger TA; Becknell B; Blaser BW; Caligiuri MA
    Expert Opin Biol Ther; 2003 Apr; 3(2):237-50. PubMed ID: 12662139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.
    Tarazona R; Sanchez-Correa B; Casas-Avilés I; Campos C; Pera A; Morgado S; López-Sejas N; Hassouneh F; Bergua JM; Arcos MJ; Bañas H; Casado JG; Durán E; Labella F; Solana R
    Cancer Immunol Immunother; 2017 Feb; 66(2):233-245. PubMed ID: 27530271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biology and clinical impact of human natural killer cells.
    Farag SS; VanDeusen JB; Fehniger TA; Caligiuri MA
    Int J Hematol; 2003 Jul; 78(1):7-17. PubMed ID: 12894845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
    Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
    Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
    Kennedy PR; Felices M; Miller JS
    Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
    Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
    Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.
    Voskens CJ; Watanabe R; Rollins S; Campana D; Hasumi K; Mann DL
    J Exp Clin Cancer Res; 2010 Oct; 29(1):134. PubMed ID: 20937115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
    Smits NC; Coupet TA; Godbersen C; Sentman CL
    Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.
    Arina A; Murillo O; Dubrot J; Azpilikueta A; Alfaro C; Pérez-Gracia JL; Bendandi M; Palencia B; Hervás-Stubbs S; Melero I
    Expert Opin Biol Ther; 2007 May; 7(5):599-615. PubMed ID: 17477799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cell receptors: alterations and therapeutic targeting in malignancies.
    Konjević G; Vuletić A; Mirjačić Martinović K
    Immunol Res; 2016 Feb; 64(1):25-35. PubMed ID: 26374324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted cellular therapy with natural killer cells.
    Klingemann H; Boissel L
    Horm Metab Res; 2008 Feb; 40(2):122-5. PubMed ID: 18283630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cells and cancer.
    Zamai L; Ponti C; Mirandola P; Gobbi G; Papa S; Galeotti L; Cocco L; Vitale M
    J Immunol; 2007 Apr; 178(7):4011-6. PubMed ID: 17371953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
    Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
    Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.
    Shenouda MM; Gillgrass A; Nham T; Hogg R; Lee AJ; Chew MV; Shafaei M; Aarts C; Lee DA; Hassell J; Bane A; Dhesy-Thind S; Ashkar AA
    Breast Cancer Res; 2017 Jul; 19(1):76. PubMed ID: 28668076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells--new understanding of basic biology may lead to more effective allogeneic haematopoietic stem cell transplantation.
    Patil S; Schwarer T
    Intern Med J; 2009 Oct; 39(10):639-47. PubMed ID: 19686544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
    Barrow AD; Colonna M
    Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biology of natural killer cells and implications for therapy of human disease.
    Chiorean EG; Miller JS
    J Hematother Stem Cell Res; 2001 Aug; 10(4):451-63. PubMed ID: 11522229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside.
    Woan KV; Miller JS
    Cancer Immunol Res; 2019 Nov; 7(11):1742-1747. PubMed ID: 31676567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.